6 New Hep C Abstracts Links

[Guest guest]

Progress in the development of preventive and therapeutic vaccines for hepatitis

C virus

Journal of Hepatology

Association of caffeine intake and histological features of chronic hepatitis C

Journal of Hepatology

Can antiviral therapy for hepatitis C reduce the prevalence of HCV among

injecting drug user populations? A modeling analysis of its prevention utility

Journal of Hepatology

The effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus

Hepatology

Th17 cells are increased with severity of liver inflammation in patients with

chronic hepatitis C

Journal of Gastroenterology and Hepatology

All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated

From the PharmaLive.com News Archive - May. 26, 2011

Pharmasset announced today the initiation of a Phase 2a trial investigating the

combination of Pharmasset's PSI-7977, a nucleotide polymerase inhibitor, and

BMS-790052, Bristol-Myers Squibb Company's NS5A replication complex inhibitor,

for the treatment of chronic hepatitis C (HCV). This trial is the result of a

clinical collaboration agreement between Pharmasset and Bristol-Myers Squibb

announced in January 2011.

[Guest guest]

Progress in the development of preventive and therapeutic vaccines for hepatitis

C virus

Journal of Hepatology

Association of caffeine intake and histological features of chronic hepatitis C

Journal of Hepatology

Can antiviral therapy for hepatitis C reduce the prevalence of HCV among

injecting drug user populations? A modeling analysis of its prevention utility

Journal of Hepatology

The effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus

Hepatology

Th17 cells are increased with severity of liver inflammation in patients with

chronic hepatitis C

Journal of Gastroenterology and Hepatology

All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated

From the PharmaLive.com News Archive - May. 26, 2011

Pharmasset announced today the initiation of a Phase 2a trial investigating the

combination of Pharmasset's PSI-7977, a nucleotide polymerase inhibitor, and

BMS-790052, Bristol-Myers Squibb Company's NS5A replication complex inhibitor,

for the treatment of chronic hepatitis C (HCV). This trial is the result of a

clinical collaboration agreement between Pharmasset and Bristol-Myers Squibb

announced in January 2011.